Asthma drug also helps protect against several food allergies

Image
ANI Washington
Last Updated : Mar 01 2014 | 5:15 PM IST

Researchers have said that an asthma drug omalizumab accelerates the process of desensitizing patients with food allergies to several foods at the same time.

The findings by researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford come on the heels of a recent study by the same team showing that people with multiple food allergies can be desensitized to several foods at once.

In the earlier study, in which patients were not given omalizumab, 25 children and adults with multiple allergies ate tiny doses of their allergens - as many as five - as highly purified food powders each day. The total dose was evenly divided between the allergens so that each subject got the same total quantity of food protein, regardless of the number of foods they were being desensitized to. The researchers monitored the treatment's safety, noting some mild allergic reactions, such as itching in the mouth, and a small number of severe reactions that were treated with epinephrine. The food dose was gradually increased until subjects could eat 4 grams of each food protein, or up to 20 grams of the allergenic food proteins in total, without experiencing a reaction. This occurred at a median of 85 weeks after food doses began.

In the second and most recent study, 25 children and adults with multiple food allergies underwent a similar protocol - but with an additional step. Eight weeks before being introduced to food allergens, the patients began receiving injections of omalizumab. This drug reduces activity of the body's IgE molecules, the antibodies involved in allergic responses, and had been shown in a previous Stanford study to speed the success of oral immunotherapy for children with milk allergies.

Patients getting omalizumab tolerated larger initial doses of allergens than those in the non-omalizumab study, and desensitization progressed faster.

The results have been published online in the journal Allergy, Asthma and Clinical Immunology.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 01 2014 | 12:40 PM IST

Next Story